18 researched Comp entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Reduce quota 30–50% in year 1; cap commission at 75% of standard rate for inherited revenue. Year 2: gradual quota normalization; year 3 full comp structure. An AE inheriting $3M existing ARR shouldn't earn the same commission rate as one h…
Read full answer ↗Inside Sales (SDR + BDR): $50k–$80k OTE. Field Sales (AE): $120k–$180k OTE at $30k ACV. Inside reps close low-touch deals ($5k–$30k); field AEs land $30k+ with travel, relationship-building, enterprise buying committees. Field AE OTE is 2–2…
Read full answer ↗Split comp: 60% new-customer AE commission rate, 40% expansion/retention CSM bonus. E.g., $200k OTE AE + $80k retention pool (monthly basis). AE component stays traditional (5% on new ARR); CSM component is fixed monthly bonus on book healt…
Read full answer ↗NYC: $450k–$550k base. SF: $500k–$600k base. Remote: $380k–$450k base. Location multipliers reflect cost of living and labor market density. CRO base (without bonus, equity, SPIFFs) is 55–65% of total OTE. A $750k OTE CRO in NYC takes home …
Read full answer ↗Use Quota Leverage: same commission rate, different quota. A territory with $50M TAM gets $300k annual quota; a $5M TAM territory gets $50k quota. Both AEs earn 5% commission on attainment. This is fair, transparent, and prevents the low-TA…
Read full answer ↗Monthly micro-SPIFFs ($2k–$5k for specific actions) beat one Q4 mega-SPIFF. A $10k SPIFF announced Oct 1 creates false pipeline urgency Oct 15–31; teams tank Nov–Dec. Instead: recurring $3k for "enterprise logo close" or "$500k+ deal close"…
Read full answer ↗Clawback applies only to deals closed, voided within 30–90 days (customer churn, fraud, contract voided). Clawed amount: 100% of commission on voided deal. Enforce via CRM (auto-flag if AE voids deal), clear policy document (signed at hire …
Read full answer ↗Pay on demos held + AE accepted (not booked). An SDR booking a call that the AE cancels, or that doesn't qualify, doesn't create value. Paying on "booked" incentivizes calendar spam and SDR gaming (booking calls that won't convert). Paying …
Read full answer ↗$200k–$280k OTE: $120k–$160k base (55–60%), $80k–$120k variable (40–45%). A VP Sales at Series B (post-Series A, pre-Series C) carries 6–12 direct AEs, owns quota, owns pipeline velocity. Higher base than AE because they manage people; lowe…
Read full answer ↗Hard commission caps ($X per deal) de-motivate; soft caps (commission rate decline) retain. Use a rate-decline cap: commission stays 1.5x at 125% quota, then drops to 1.2x at 150%, then 1.0x at 175%+. This lets a top AE earning $400k feel l…
Read full answer ↗Typical SaaS AE accelerators run 1.5x-2.0x past 100% of quota with a second jump to 2.5x-3.0x past 125%, capped or decelerated past 150-200% to protect plan economics. Cross-survey median (Bridge Group 2025 SaaS AE Metrics n=412, Pavilion 2…
Read full answer ↗Pay 100% of base salary for the first 90 days with zero commission, then phase commission on 50% of full quota in months 4-6, 75% in months 7-9, and 100% from month 10 onward — with declining-base draw-against-future-commission as the optio…
Read full answer ↗Base $475k–$525k (55–60% of OTE), variable $325k–$425k (40–45%) at $850k–$950k OTE — plus $150k–$250k/yr equity vest (RSUs) and 0.10–0.25% fully diluted refresh — is the defensible 50/50-leaning split for a CRO running a $50M ARR private Sa…
Read full answer ↗Pay SDRs on Sales-Accepted Leads (SALs) or held meetings — never on raw MQLs. Stack a 30-day AE accept window, a conversion-floor SPIF, and a clawback so the only way to "game" the plan is to actually source qualified pipeline. Bridge Group…
Read full answer ↗Fair OTE for an enterprise AE selling $100k+ ACV deals in 2026 is $230k–$280k base case, with top-quartile pull at $300k–$400k+ at late-stage SaaS. The honest answer depends on three variables: company stage, vertical (data infra and securi…
Read full answer ↗Biotech B2B Sales Org: Quota Structure for Long-Cycle Clinical Trials Quick take: Biotech sales orgs running 18–36 month deal cycles can't use traditional annual quota. They layer multi-year revenue recognition, pipeline-weighted OTE, and m…
Read full answer ↗Quick take: Quantum computing startups don't have a meaningfully different AE comp philosophy — they're still chasing ARR and pipeline coverage. But the execution is radically different: longer sales cycles (18–36 months vs. 6–12), smaller …
Read full answer ↗I'll search for the latest benchmarks on SDR compensation structures and accelerator design in 2025-2027. Quick Take A 100-rep RevOps team building SDR accelerators in 2027 needs to move past "one-size-fits-all" bonus tiers. The leverage po…
Read full answer ↗